Trial reportEuropean journal of nuclear medicine and molecular imaging2014
FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).
Trial report in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01261598 (Predictive Value of FDG-TEP During Radiotherapy), which is not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Predictive Value of FDG-TEP During Radiotherapy (RT) or Chemo-radiotherapy (CRT) in Patients With Non Small Cell Lung Cancer on the One-year Survival
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2018Pooled it
- Role of interimEuropean journal of nuclear medicine and molecular imaging · 2017Pooled it
- Regional Lymph Node Uptake of [(18)F]Fluorodeoxyglucose After Definitive Chemoradiation Therapy Predicts Local-Regional Failure of Locally Advanced Non-Small Cell Lung Cancer: Results of ACRIN 6668/RTOG 0235.International journal of radiation oncology, biology, physics · 2015Trial
- Integrating ctDNA Analysis and Radiomics for Dynamic Risk Assessment in Localized Lung Cancer.Cancer discovery · 2025Article
- Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A novel analytical approach for outcome prediction in newly diagnosed NSCLC based on [European radiology · 2023Article
- Personalized mid-course FDG-PET based adaptive treatment planning for non-small cell lung cancer using machine learning and optimization.Physics in medicine and biology · 2022Article
- Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[European journal of nuclear medicine and molecular imaging · 2022Review
- Liquid Biopsies for Molecular Biology-Based Radiotherapy.International journal of molecular sciences · 2021Review
- Update on Quantitative Imaging for Predicting and Assessing Response in Oncology.Seminars in nuclear medicine · 2020Review
- Precision radiotherapy for non-small cell lung cancer.Journal of biomedical science · 2020Review
- Prognostic value of volumetric metabolic parameter changes determined by during and after radiotherapy-basedThe Kaohsiung journal of medical sciences · 2019Article
- Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.PloS one · 2019Article
- Delineation of lung cancer with FDG PET/CT during radiation therapy.Radiation oncology (London, England) · 2018Article
- The role ofEuropean radiology · 2017Article
- Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.The British journal of radiology · 2017Review
- Article
- An alternative parameter for early forecasting clinical response in NSCLC patients during radiotherapy: proof of concept study.The British journal of radiology · 2016Article
- Image-derived biomarkers and multimodal imaging strategies for lung cancer management.European journal of nuclear medicine and molecular imaging · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess prospectively the prognostic value of FDG PET/CT during curative-intent radiotherapy (RT) with or without concomitant chemotherapy in patients with non-small-cell lung cancer (NSCLC).
methodsPatients with histological proof of invasive localized NSCLC and evaluable tumour, and who were candidates for curative-intent radiochemotherapy (RCT) or RT were preincluded after providing written informed consent. Definitive inclusion was conditional upon significant FDG uptake before RT (PET₁). All included patients had a FDG PET/CT scan during RT (PET₂, mean dose 43 Gy) and were evaluated by FDG PET/CT at 3 months and 1 year after RT. The main endpoint was death (from whatever cause) or tumour progression at 1 year.
resultsOf 77 patients preincluded, 52 were evaluable. Among the evaluable patients, 77% received RT with induction chemotherapy and 73% RT with concomitant chemotherapy. At 1 year, 40 patients (77 %) had died or had tumour progression. No statistically significant association was found between stage (IIIB vs. other), histology (squamous cell carcinoma vs. other), induction or concomitant chemotherapy, and death/tumour progression at 1 year. The SUVmax in the PET2 scan was the single variable predictive of death or tumour progression at 1 year (odds ratio 1.97, 95% CI 1.25 - 3.09, p = 0.003) in multivariate analysis. The area under the receiver operating characteristic curve was 0.85 (95% CI 0.73 - 0.94, p < 10(-4)). A SUVmax value of 5.3 in the PET₂ scan yielded a sensitivity of 70% and a specificity of 92% for predicting tumour progression or death at 1 year.
conclusionThis prospective multicentre study demonstrated the prognostic value in terms of disease-free survival of SUVmax assessed during the 5th week of curative-intent RT or RCT in NSCLC patients (NCT01261598; RTEP2 study).
Indexed as
Identifiers
24562641What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.